Abstract
The presence of measurable residual disease (MRD) is strongly associated with treatment outcomes in acute myeloid leukemia (AML). Despite the correlation with clinical outcomes, MRD assessment has yet to be standardized or routinely incorporated into clinical trials. Discrepancies have been observed between different techniques for MRD assessment and there remains a need to compare centralized, high-quality multiparametric flow cytometry (MFC) and ultrasensitive next-generation sequencing (NGS) in AML patients with diverse mutational profiles. In 62 patients with AML, aged 18-60, in first complete remission after intensive induction therapy on the randomized phase 3 SWOG-S0106 clinical trial, MRD detection by MFC was compared with a 29 gene panel utilizing duplex sequencing (DS), an NGS method that generates double-stranded consensus sequences to reduce false positive errors. Using DS, detection of a persistent mutation utilizing defined criteria was seen in 22 (35%) patients and was strongly associated with higher rates of relapse (68% vs 13% at year 5; HR, 8.8; 95% CI, 3.2-24.5; P<0.001) and decreased survival (32% vs 82% at year 5; HR, 5.6; 95% CI, 2.3-13.8; P<0.001). MRD as defined by DS strongly outperformed MFC, which was observed in 10 (16%) patients and marginally associated with higher rates of relapse (50% vs 30% at year 5; HR, 2.4; 95% CI, 0.9-6.7; P=0.087) and decreased survival (40% vs 68% at year 5; HR, 2.5; 95% CI, 1.0-6.3; P=0.059). Furthermore, the prognostic significance of DS MRD status at the time of remission was similar on both randomized arms of the trial, predicting S0106 clinical trial outcomes. These findings suggest that DS is a powerful tool that could be used in patient management and for early treatment assessment in clinical trials.
Competing Interest Statement
The National Heart, Lung, and Blood Institute receives research funding for the laboratory of CSH from Sellas and the Foundation of the NIH AML MRD Biomarkers Consortium. MO consults for Merck and Biosight and serves on the data safety monitoring committee for Celgene, Glycomimetic, and Grifols. JH, THS, CCV, ES, and JJS are employees and stockholders of TwinStrand Biosciences. BLW consults for Amgen and Kite Pharma. HE: COI: AbbVie; Agios Pharmaceuticals; ALX Oncology; Amgen; Daiichi Sankyo; FORMA Therapeutics; Forty Seven; Gilead Sciences; GlycoMimetics; ImmunoGen; Jazz Pharmaceuticals; MacroGenics; Novartis; PTC Therapeutics; Research Funding: AbbVie; Agios Pharmaceuticals; Bristol Myers Squibb; Celgene; Incyte Corporation; Jazz Pharmaceuticals; Novartis; Speakers Bureau: AbbVie; Independent review committee: AbbVie; Agios Pharmaceuticals; Astellas; Bristol Myers Squibb; Celgene; Daiichi Sankyo; Genentech; GlycoMimetics; Incyte Corporation; Jazz Pharmaceuticals; Kura Oncology.
Clinical Trial
NCT00085709
Funding Statement
This work was supported in part by the Intramural Research Program of the National Heart, Lung, and Blood Institute (CSH); National Cancer Institute of the National Institutes of Health under Award Number R44CA233381 (JS); and National Cancer Institute CA175008, 180888, 180819, 233338, and 233381 (JPR).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional review boards of of the Fred Hutchinson Cancer Center gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All raw sequencing data produced are available online at the NCBI Small Reads Archive (Accession: PRJNA945188)